Merck, Schering-Plough Get Boosted After Beating Forecasts

Sales of cholesterol drugs help send Merck shares to a new 52-week high

Merck & Co. (MRK) and Schering-Plough Corp. (SGP) reported stronger-than-expected third quarter results on Oct. 20, with help from their joint sales of cholesterol drugs. But Merck's earnings were far weaker as the Whitehouse Station, N.J.-based company slashes costs, fights generics and deals with legal battles.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.